Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Pharmacological induction of hypoxia-inducible transcription factor ARNT attenuates chronic kidney failure
Björn Tampe, … , Samy Hakroush, Michael Zeisberg
Björn Tampe, … , Samy Hakroush, Michael Zeisberg
Published April 17, 2018
Citation Information: J Clin Invest. 2018;128(7):3053-3070. https://doi.org/10.1172/JCI89632.
View: Text | PDF
Research Article Nephrology

Pharmacological induction of hypoxia-inducible transcription factor ARNT attenuates chronic kidney failure

  • Text
  • PDF
Abstract

Progression of chronic kidney disease associated with progressive fibrosis and impaired tubular epithelial regeneration is still an unmet biomedical challenge because, once chronic lesions have manifested, no effective therapies are available as of yet for clinical use. Prompted by various studies across multiple organs demonstrating that preconditioning regimens to induce endogenous regenerative mechanisms protect various organs from later incurring acute injuries, we here aimed to gain insights into the molecular mechanisms underlying successful protection and to explore whether such pathways could be utilized to inhibit progression of chronic organ injury. We identified a protective mechanism controlled by the transcription factor ARNT that effectively inhibits progression of chronic kidney injury by transcriptional induction of ALK3, the principal mediator of antifibrotic and proregenerative bone morphogenetic protein–signaling (BMP-signaling) responses. We further report that ARNT expression itself is controlled by the FKBP12/YY1 transcriptional repressor complex and that disruption of such FKBP12/YY1 complexes by picomolar FK506 at subimmunosuppressive doses increases ARNT expression, subsequently leading to homodimeric ARNT-induced ALK3 transcription. Direct targeting of FKBP12/YY1 with in vivo morpholino approaches or small molecule inhibitors, including GPI-1046, was equally effective for inducing ARNT expression, with subsequent activation of ALK3-dependent canonical BMP-signaling responses and attenuated chronic organ failure in models of chronic kidney disease, and also cardiac and liver injuries. In summary, we report an organ-protective mechanism that can be pharmacologically modulated by immunophilin ligands FK506 and GPI-1046 or therapeutically targeted by in vivo morpholino approaches.

Authors

Björn Tampe, Désirée Tampe, Gunsmaa Nyamsuren, Friederike Klöpper, Gregor Rapp, Anne Kauffels, Thomas Lorf, Elisabeth M. Zeisberg, Gerhard A. Müller, Raghu Kalluri, Samy Hakroush, Michael Zeisberg

×

Figure 7

Evidence for Arnt homodimer formation in mice treated with FK506.

Options: View larger image (or click on image) Download as PowerPoint
Evidence for Arnt homodimer formation in mice treated with FK506.
(A and...
(A and B) Representative kidney sections of γGTcre+;Yy1fl/fl and γGTcre–;Yy1fl/fl control mice immunolabeled with primary antibodies against Arnt are shown. n = 3/group. Data are presented as mean ± SD. **P < 0.01; ***P < 0.001, 1-way ANOVA with Bonferroni’s post hoc analysis. (C–E) Arnt protein levels were analyzed by immunoblotting and immunostaining. Scale bars: 25 μm. n = 6/group. Data are presented as mean ± SD. ***P < 0.001; #P < 0.0001, 1-way ANOVA with Bonferroni’s post hoc analysis. (F) Dimer formation of Arnt/Arnt, Arnt/Hif1α, Arnt/Hif2α, and Arnt/Ahr in total kidney lysates was assessed by native gel electrophoresis after Arnt pulldown. See complete unedited blots in the supplemental material.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts